Press Releases

NASDAQ
SPPI
$11.79
+0.09
DAY HI:
$11.98
DAY LOW:
$11.69
VOLUME:
276,206
2:27 PM EST 02/15/19

Press Releases

Date Title View PDF
May 3, 2018 Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update
May 3, 2018 Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center
May 1, 2018 Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific
Apr 30, 2018 Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes
Apr 27, 2018 Company Profile for SPECTRUM PHARMACEUTICALS
Apr 26, 2018 Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast
Apr 23, 2018 Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine
Apr 17, 2018 Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago
Apr 10, 2018 Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients
Apr 3, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th
Mar 7, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the Cowen and Company 38th Annual Health Care Conference on March 13th
Mar 6, 2018 Spectrum Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results and Pipeline Update
Feb 27, 2018 Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors
Feb 26, 2018 Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results Teleconference and Webcast
Feb 15, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd
Feb 5, 2018 Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study
Jan 23, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the Noble Capital Markets' Fourteenth Annual Investor Conference
Dec 17, 2017 Spectrum Pharmaceuticals Announces Leadership Changes
Dec 13, 2017 Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)
Dec 4, 2017 Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017
Nov 8, 2017 Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th
Nov 2, 2017 Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update
Oct 30, 2017 Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2
Oct 26, 2017 Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast
Oct 17, 2017 Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
Displaying records 26 - 50 of 766